These gain-of-function ALK mutations are reported as constitutively active ALK mutations found in human neuroblastoma patients, with ALK-F1174L being a more frequently occurring ‘hot-spot’ mutation (Fig. 1B,C) (Umapathy et al., 2019; Vasseur et al., 2019). This evidence concerns the gene ALK and neuroblastoma.